Ono and Medarex Enter Into Second Collaboration for the Development of a Fully Human Antibody Therapeutic

30-Mar-2006

Ono Pharmaceutical Co., Ltd. and Medarex, Inc. announced that they have entered into a collaborative agreement to research and develop a fully human anti-SDF-1 antibody for the potential treatment of multiple indications. This is the second antibody development collaboration between Ono and Medarex. Anti-SDF-1 antibodies have been raised utilizing Medarex's UltiMAb Human Antibody Development System(R).

SDF-1 (Stromal cell-Derived Factor 1) is a member of the chemokine protein family whose members are involved in cell migration. SDF-1 has been implicated in a variety of diseases, and it is anticipated that blocking functions of SDF-1 could lead to uses in multiple therapeutic indications.

Under this collaboration, Ono and Medarex expect to jointly work toward potential commercialization of a fully human antibody. The two companies plan to share the costs and responsibilities of research and product development up to the completion of a Phase II clinical study. Thereafter, each company will be fully responsible for any continued development and any commercialization in its exclusive territory; Medarex's exclusive territory is North America, and Ono's exclusive territory is all areas outside of North America.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous